Challenges and Emerging Solutions in Upper GI Disorders
March 13, 2017
Drs. Colin Howden and Nimish Vakil (pictured) debrief on the AGA Drug Development Conference in the March issue of Gastro.
If you are challenged by lack of options when caring for patients with upper GI disorders, you’ll want to check out a brief report in the March issue of Gastroenterology about AGA’s recent Drug Development Conference, which was hosted by the AGA Center for Diagnostics and Therapeutics.
Over a two-day period, researchers, clinicians, FDA personnel, and representatives of the pharmaceutical industry and patient advocacy groups convened in Washington, DC, to discuss current unmet needs and future strategies in clinical development for GERD, eosinophilic esophagitis, gastroparesis and functional dyspepsia.
Writing in Gastroenterology, CDT scientific advisory board members Drs. Colin Howden and Nimish Vakil say that they “hope that the stimulating discussion will help to encourage progress in these disorders which are responsible for so much morbidity and health care costs.”
A series of in-depth white papers about each of the four disease states covered by the conference will run in future issues Clinical Gastroenterology and Hepatology. In the meantime, read the brief report in Gastroenterology about the discussions related to these often difficult-to-manage upper GI disorders.